ライフサイエンスコーパス: disease model

1 dothelial functions in vitro, in vivo and in disease model.

2 5Y cells, a widely used in vitro Parkinson's disease model.

3 votal role in inflammation in a mouse kidney disease model.

4 as assessed in a skin challenge and invasive disease model.

5 , fatty acids and steroids in a Huntington's disease model.

6 In this study we used melanoma as a disease model.

7 onses using a severe acute graft versus host disease model.

8 ffector CD8 T cell response to an infectious disease model.

9 organ level, in a dysmotile gastrointestinal disease model.

10 ptic terminals in a murine WNV neuroinvasive disease model.

11 as well as in an in vivo inflammatory bowel disease model.

12 n antifibrotic effect of PPIs using IPF as a disease model.

13 ower of key signatures characteristic of the disease model.

14 ease model, which is the simplest multistate disease model.

15 committed to the application of the medical disease model.

16 nvestigated in a well-established alphavirus disease model.

17 tion of PNEC secretion of GABA in a neonatal disease model.

18 he development of atherosclerosis in a mouse disease model.

19 l myasthenic syndrome type 19 and serve as a disease model.

20 d treatments shown to be effective in animal disease models.

21 uction may contribute to effects observed in disease models.

22 udied both in vitro and in vivo using animal disease models.

23 cular changes upon drug treatment in various disease models.

24 thought to cause inflammation in necroptotic disease models.

25 has neuroprotective effects in Huntington's disease models.

26 protects mice from pathological bone loss in disease models.

27 ies and pathogenicity in murine inflammatory disease models.

28 trongest female-bias was found in infectious disease models.

29 ted by genetic manipulation of DNA repair in disease models.

30 of disease, and permit the use of tractable disease models.

31 ponse of mice to three distinct inflammatory disease models.

32 europrotective efficacy in many neurological disease models.

33 structure-based approach, can be assessed in disease models.

34 formation about drug activity within complex disease models.

35 operties suitable for application in in vivo disease models.

36 e observed in psychiatric illness, in animal disease models.

37 tress response factors protective in amyloid disease models.

38 on in renal cells and in experimental kidney disease models.

39 properties in ischemic stroke and Huntington disease models.

40 sed to generate patient- and tissue-specific disease models.

41 rged as a key player in various inflammatory disease models.

42 to have protective effects in several renal disease models.

43 s therapeutic effects in various preclinical disease models.

44 regulation or knock-out improves outcomes in disease models.

45 g towards heart failure in 2 surgery-induced disease models.

46 s, stem-cell differentiation data and animal disease models.

47 th patients with heart disease and in rodent disease models.

48 adaptive immune responses and in autoimmune disease models.

49 ice tau appropriately in order to be used as disease models.

50 d microglia of normal white matter in myelin disease models.

51 ated in autoimmune diseases and inflammatory disease models.

52 mplications of mechanistic studies in animal disease models.

53 ith an emphasis on its origin, genetics, and disease models.

54 ed, including pharmacological treatments and disease models.

55 nctional reorganization of brain circuits in disease models.

56 evelopment of personalized, in vitro cardiac disease models.

57 role of the inflammasome in a wide range of disease models.

58 is required for injury responses in diverse disease models.

59 expression patterns, and generation of human disease models.

60 tects oligodendrocyte lineage cells in other disease models.

61 ely alleviated symptoms in mouse Parkinson's disease models.

62 acterization and validation in complementary disease models.

63 em cell biology to regenerative medicine and disease modeling.

64 pplications such as early drug screening and disease modeling.

65 ts an important tool in drug development and disease modeling.

66 t utility in regenerative medicine and human disease modeling.

67 n for their use in clinical applications and disease modeling.

68 for recapitulating human gene expression and disease modeling.

69 despread in vitro models for development and disease modeling.

70 drug testing, high-throughput screening, and disease modeling.

71 ental platforms that may be instrumental for disease modeling.

72 vis as a subject for biological research and disease modeling.

73 ing the production of genome-edited pigs for disease modeling.

74 d, creating a rich public resource for human disease modelling.

75 s a new strategy for tissue regeneration and disease modelling.

76 rdiomyocytes are well established as cardiac disease model..

77 of TR1 cells in a murine inflammatory bowel disease model, a model that resembles the trials perform

78 and offer simple solutions that may improve disease model accuracy.

79 In preclinical disease models, activating FcgammaRs promote atheroscler

80 that the diabetic ob/ob genotype and the MCD disease model alter kidney transporter expression and al

81 ting Tregs in a xenogeneic graft-versus-host disease model and in adoptive transfer models of experim

82 the initialization and parametrization of a disease model and show that this allows us to determine

83 on characteristics in a transient arrhythmia disease model and subsequent tissue self-adaptation.

84 t strains followed by selection in an animal disease model and whole-genome sequence analysis.

85 ecapitulates the pathology of a conventional disease model and/or human food allergy.

86 int mutation has been an invaluable tool for disease modeling and analysis.

87 should facilitate hPSC-based strategies for disease modeling and cell therapy in CNS disorders.

88 he potential of hPSC-derived neural cells in disease modeling and cell therapy.

89 method could advance the use of hiPSC-CM for disease modeling and cell-based therapy.

90 ilitate applications for tissue engineering, disease modeling and chemical screening.

91 vo organs are pushing the frontiers of human disease modeling and drug development.

92 for deriving human COs, which can be used in disease modeling and drug discovery for colorectal disea

93 luripotent stem cells (hiPSCs) are useful in disease modeling and drug discovery, and they promise to

94 ive medicine, and provides a unique tool for disease modeling and drug discovery.

95 imiting the ability to use EHM for iPS-based disease modeling and drug screening.

96 controlling biliary development, as well as disease modeling and drug screening.

97 s of hepatic and biliary development and for disease modeling and drug screening.

98 has important implications for their use in disease modeling and drug testing.

99 c cell types is crucial for patient-specific disease modeling and drug testing.

100 broad applications for cholangiopathies, in disease modeling and for screening of therapeutic compou

101 us, PSC-derived AEC2s provide a platform for disease modeling and future functional regeneration of t

102 o explore how this new culture system allows disease modeling and gene repair for a personalized rege

103 gineering of macroscale human myocardium for disease modeling and heart repair from embryonic and ind

104 eed for a paradigm shift towards integrative disease modeling and neuroimaging biomarker-guided preci

105 ers unprecedented opportunities for in vitro disease modeling and personalized cell replacement thera

106 ng patient-specific differentiated cells for disease modeling and preclinical drug testing.

107 This method will be useful for disease modeling and provides a means of rapidly editing

108 Current efforts in cellular disease modeling and regenerative medicine are limited b

109 uripotent stem cell (PSC)-derived neurons in disease modeling and regenerative medicine requires anal

110 tine application of hPSC-derived lineages in disease modeling and regenerative medicine.

111 stem cell (iPSC) lines remains a concern for disease modeling and regenerative medicine.

112 nes and have potential applications for both disease modeling and regenerative medicine.

113 lopment provides a new and scalable tool for disease modeling and therapeutic screening.

114 duced pluripotency is a promising avenue for disease modeling and therapy, but the molecular principl

115 Human iPS cells hold great promise for disease modeling and treatment of degenerative disorders

116 ryonic stem cells to specific cell types for disease modelling and cell replacement therapy.

117 o be a useful tool for cell-based therapies, disease modelling and drug discovery.

118 ardiogenesis, and as a platform for vascular disease modelling and drug screening.

119 suggests certain advantages for their use in disease modelling and regenerative medicine.

120 hould prove powerful and versatile tools for disease modelling and therapeutic experimentation.

121 This study emphasises the value of PSCs for disease modelling and underlines the significance of in

122 ug loading, and applications in experimental disease models and clinic are discussed.

123 tory and immunomodulatory effects in various disease models and clinical treatments.

124 this review article, we introduce multistate disease models and competing risks analysis and explain

125 to Parkinson's disease-like damage in rodent disease models and considered in clinical association st

126 ses of stem cell science to generate precise disease models and designer cell samples for personalize

127 ssection of canonical NF-kappaB signaling in disease models and healthy tissues, the success of the s

128 greatly reduced in samples from Huntington's disease models and in Huntington's disease patients, and

129 d detect DNA methylation dynamics in in vivo disease models and in limited clinical samples.

130 ge-guided FE method can be extended to other disease models and is amenable to clinical translation f

131 nhibition is beneficial in neurodegenerative disease models and its effects are often attributable to

132 clear in part due to the lack of appropriate disease models and the absence of a simple method for th

133 est male-bias was observed in cardiovascular disease models and the strongest female-bias was found i

134 and better prospects for accurate infectious diseases models and forecasts.

135 ta oligomer model), Tg2576 mice (Alzheimer's disease model), and tau609 mice (tauopathy model).

136 s a scalable cell source for drug discovery, disease modeling, and cardiac regenerative therapy.

137 has broad applicability for basic research, disease modeling, and clinical application.

138 as generated opportunities for heart repair, disease modeling, and drug development.

139 velopmental biology, regenerative therapies, disease modeling, and drug discovery.

140 human model system in regenerative medicine, disease modeling, and drug screening.

141 al for use in hematopoietic cell production, disease modeling, and eventually transplantation medicin

142 rces in order to support precision medicine, disease modeling, and mechanistic exploration.

143 mous potential as models for drug screening, disease modeling, and regenerative medicine.

144 ul and exciting tool for tissue engineering, disease modeling, and regenerative medicine.

145 re suitable for in vitro myelination assays, disease modeling, and screening of pharmacological compo

146 man responses are needed for drug screening, disease modeling, and, ultimately, kidney organ engineer

147 ajor impacts on the predictions of behaviour-disease models, and further study of such processes in t

148 g, help define disease mechanisms, establish disease models, and provide a basis for translational re

149 ablishing effectiveness of TAS2R agonists in disease models are lacking.

150 Despite this, nearly all in vitro disease models are mechanically static.

151 obiology of autism spectrum disorders, valid disease models are pivotal.

152 is heterogeneous group of diseases, adequate disease models are required in order to better understan

153 de dose range in the cotton rat RSV enhanced-disease model, as suboptimal dosing of several RSV F sub

154 Often disease models assume contacts are equal and use mean fi

155 high-content screening of various C. elegans disease models at the speed and cost of in vitro cell-ba

156 advances in the research fields of genetics, disease modelling, biomarkers, and therapeutic strategie

157 quantitative group comparisons of normal and disease model brain cells for the whole brain at a high

158 vivo mechanistic model and a chronic in vivo disease model but suffers from tolerability issues upon

159 This new concept of metabolic disease modeling by somatic genome editing could be appl

160 The data were validated using a computerized disease model called DisMod II.

161 While dynamic disease models can provide a better understanding of the

162 We show in a Chinese hamster ovary (CHO) disease model cell line and mouse embryonic stem (ES) ce

163 Using a disease model characterized by increased sUA levels, we

164 ting one of the earliest defects observed in disease models, contributing to denervation and motoneur

165 The cohort was considered as a multistate disease model, cumulative incidences (CumIs) of events w

166 pplication of cardiac tissue engineering for disease modeling, drug development, and cardiac repair.

167 ngle-cell level, which should be valuable to disease modeling, drug discovery, and preclinical cardio

168 constitute a potential cell source for heart disease modeling, drug screening, and cell-based therape

169 remains a key challenge for applications in disease modeling, drug screening, and heart repair.

170 nal mutagenesis should have broad utility in disease modeling, drug screening, and regenerative medic

171 nes for myogenic genes which can be used for disease modeling, drug screening, gene correction and fu

172 PSCs, hold great potential for personalized disease modeling, drug testing and cell-based therapeuti

173 Pigs represent ideal human disease models due to their similar size, anatomy, metab

174 nate immunity, we exploited a unique mucosal disease model, endometritis, where inflammation is a con

175 l symptoms and oxidative stress in Alexander disease model flies and mice.

176 EIVPD was related to the severity of liver disease (Model for End-Stage Liver Disease, rho = 0.45,

177 ompound heterozygous architectures, a common disease model for recessive monogenic disorders, where t

178 A lack of relevant disease models for Campylobacter jejuni has long been an

179 role in these diseases and provide tractable disease models for further investigation, we analyzed th

180 main focus is on the creation of new primate disease models for understanding the pathological mechan

181 ophila galactosemia I (dGALT) and II (dGALK) disease models genetically interact; manifesting deficit

182 Animal disease models had revealed the antithetic effects of th

183 Although most neuropsychiatric disease modeling has focused on genes disrupted by rare,

184 their application in tissue engineering and disease modeling have great potential to advance innovat

185 e period, useful mouse and non-human primate disease models have been established, and pre-clinical e

186 Network-based infectious disease models have been highly effective in elucidating

187 licable to other developmental questions and disease models, highlighting the power of relatively sma

188 been shown to be expressed on DCs in several disease models, however, its role in asthma is yet to be

189 tion suppressed pathological angiogenesis in disease models, identifying MAP4K4 as a potential therap

190 In both disease models, IL-4Ralpha-responsive B cells displayed

191 ly members, prioritizing variants assuming a disease model, imputation of untyped variants, and linka

192 ight that better approximates the underlying disease model in a data-adaptive manner.

193 Although human disease modeling in flies may still be rather novel, rec

194 create patient-specific mutations for human disease modeling in Xenopus.

195 it an ideal platform for drug discovery and disease modelling in the fields of human neurodegenerati

196 vances have been made in terms of developing disease models in animals, such as transgenic mice, many

197 nology has been used widely to develop human disease models in laboratory animals and to study gene f

198 s tools can identify phenotypically relevant disease models in research and diagnostic contexts.

199 n in vitro, in living cells, and in multiple disease models in vivo.

200 and protective effects when administered in disease models, in part, by reducing neutrophil infiltra

201 in neurodegenerative and other inflammatory disease models including chronic obstructive pulmonary d

202 and physiology than 2D cultures for numerous disease models, including cancer and polycystic kidney d

203 ion, with beneficial effects in inflammatory disease models, including septic shock.

204 Clinical studies and disease models indicate that neuropathy mainly results f

205 rioritizing the translation of findings from disease models into clinical studies.

206 results obtained with mouse neutrophils (and disease models) into enhanced understanding of human inf

207 ng a comprehensive integrated approach to ID disease modeling, involving human cellular analyses coup

208 ice for drug screening studies, when a valid disease model is available.

209 Stem cell-based disease modeling is an emerging technology for the mecha

210 Testing potential drug treatments in animal disease models is a decisive step of all preclinical dru

211 y of Mesp1-CPCs in cell culture and ischemic disease models is an important initial step toward using

212 acodynamic activity, and efficacy in chronic disease models is beneficial for enabling hypothesis-dri

213 recent rapid adoption of zebrafish as human disease models is making management of these data partic

214 18)F]BF4(-)-PET combined with NIS expressing disease models is particularly useful whenever preclinic

215 or bioengineering, cell transplantation, and disease modeling, it would be useful to establish those

216 ound 1a showed promising efficacy in several disease models, its binding to a H3 receptor as well as

217 The rising importance of infectious disease modeling makes this an appropriate time for a gu

218 to study disease progression in a multistate disease model may be called competing risks analysis, na

219 inopathies and indicates that human midbrain disease models may be useful for identifying critical th

220 cholinergic receptor expression in Alexander disease model mice and in postmortem brain tissue from A

221 t blocking muscarinic receptors in Alexander disease model mice reduces oxidative stress, emphasizing

222 Alzheimer disease model mice were then treated either by surgicall

223 onitor efficacy of this approach in Sandhoff disease model mice.

224 Toc-HDO also improves the phenotype in disease models more effectively.

225 f1) Although induced in in vivo Huntington's disease models, NPM1 protein levels are unchanged in cul

226 ny), and confocal images of an in vivo mouse disease model of aspergillus fumigatus pneumonia.

227 mental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis.

228 an experimental autoimmune encephalomyelitis disease model of neurodegeneration in multiple sclerosis

229 RGCs from hESCs, allowing future studies on disease modeling of optic neuropathies and development o

230 erapeutic implications of NAD enhancement in disease models of abnormally low NAD.

231 G2A has been implicated in disease models of autoimmunity and atherosclerosis.

232 isplayed therapeutic benefits in preclinical disease models of hemophagocytic lymphohistiocytosis and

233 f in vivo efficacy as measured by two rodent disease models of inflammation.

234 TPD significantly attenuated TACE-mediated disease models of sepsis, rheumatoid arthritis (RA) and

235 ection as well as to establish phenotypes in disease modeling or toxicity studies.

236 target for intervention in ALS patients and disease models, our data indicate that the melanocortin

237 In a complex inflammatory disease model, Plcbeta2-, Plcbeta3-, or Rac1-deficient m

238 ), have shown therapeutic effects in several disease models, prompting us to determine whether DMF is

239 bustness to mutation has had major impact on disease models, quantitative genetics, and evolutionary

240 presents a common denominator among multiple disease models ranging from cells to humans through mous

241 This is partly due to the lack of disease models recapitulating the human pathology.

242 s, and our methods are applicable to various disease models regardless whether the underlying true mo

243 gene editing in hPSCs a more viable tool for disease modeling, regenerative medicine and cell-based t

244 logy has expanded with 3 major applications: disease modeling, regenerative therapy, and drug discove

245 al, including enhanced orthology data, Human Disease Model Reports, protein domain search and visuali

246 r, administration of Bis-T-23 in these renal disease models restored the normal ultrastructure of pod

247 This strategy, based on linear progression disease models, resulted in selective detection of BE th

248 kidneys from previously examined murine NCGN disease models revealed NF-kappaB activation in affected

249 Final validation into a skin disease model showed that impaired autophagy contributes

250 Disease models simplify reality and cannot capture all b

251 pmental studies, and can further be used for disease modeling, small molecules and genetic screens, o

252 Nonetheless, many metabolic disease models still depend upon laborious germline targ

253 Recent advances in disease modeling, structural biology, and an improved un

254 yocytes (hiPSC-CMs) for drug development and disease modeling studies, methods to generate large, fun

255 it often lacks the scalability required for disease modeling studies.

256 vo potential functions of PAK4 in pancreatic disease models such as for pancreatitis and different pa

257 n (VNS) is effective in various inflammatory disease models, such as rheumatoid arthritis and inflamm

258 tcomes in all three interacting galactosemia disease models, suggest that Futsch homolog MAP1B and th

259 ibition confers resistance in various animal disease models, suggesting that inflammation caused by n

260 rity of P. aeruginosa mutants varied between disease models, suggesting that virulence is dependent o

261 stic studies using Itpkc-deficient mice in a disease model support the genomic, cellular, and clinica

262 y, these experiments establish a progressive disease model that can contribute toward identifying the

263 acilitated the development of human cellular disease models that can be used to study pathogenesis an

264 authors describe human chronic inflammatory disease models that can help elucidate the pathophysiolo

265 been hampered for decades by the paucity of disease models that integrate molecular and functional e

266 rences in genetic background to build richer disease models that more accurately reflect the level of

267 Using mouse disease models that represent various phases in the prog

268 n the R6/2 mouse, a widely used Huntington's disease model, that integration of a rearranged transgen

269 Remarkably, in a Parkinson's disease model, the mice show normal motor behavior.

270 -the-art in both mechanistic and correlative disease modelling, the data driving these models, the ve

271 Owing to limited disease models, the etiology of NBL is largely unknown,

272 Importantly, in both disease models, the sterol-based agonists do not affect

273 models for mechanistic biological research, disease modelling, therapeutic target identification, dr

274 Furthermore, we use an in vitro disease model to demonstrate the cells respond to differ

275 Moreover, we contribute a cellular disease model to dissect the biology of AL PCs.

276 generally, we argue that bvFTD constitutes a disease model to study the neurocircuitry of complex beh

277 lying an environmentally mediated infectious disease model to the 1993 Milwaukee Cryptosporidium outb

278 d cell-ablation method was tested in several disease models to study immune cell functionalities, hep

279 uggesting that virulence is dependent on the disease model used and hence the host environment.

280 ced monosodium urate-mediated peritonitis, a disease model used for studying the consequences of NLRP

281 Extending the method to an Alzheimer's disease model, we confirm that transcriptomic changes ob

282 In the Drosophila FXS disease model, we found FMRP binds shrub mRNA (human Chm

283 erimental autoimmune encephalomyelitis (EAE) disease model, we found that OX40 stimulation inhibited

284 g natural killer/T-cell lymphoma (NKTL) as a disease model, we found that phosphorylation of EZH2 by

285 To confirm this response in a disease model, we isolated eosinophils from the livers o

286 Using our recently developed ZIKV disease model, we simulated the reported ZIKV infection

287 The cardiac disease models were administered with a locked nucleic a

288 his approach can be extended to other animal disease models where macrophages are implicated and has

289 ks analysis, named after the competing risks disease model, which is the simplest multistate disease

290 l phenotypes onto TRN dysfunction in a human disease model, while also identifying molecular and circ

291 This iPSC-derived disease model will facilitate diagnosis, studies on auto

292 ithm of odds score = 3.9), under a recessive disease model with 100% penetrance and a risk allele fre

293 n an attempt to create a liver developmental disease model with a similar phenotype to Alagille syndr

294 mouse genes, gene functions, phenotypes and disease models with a strong emphasis on the relationshi

295 ward, better integration of dynamic, spatial disease models with approaches from movement ecology, la

296 In disease models with energy and 1 or more nutrient intake

297 Tighter integration of infectious disease models with public health practice and developme

298 . aureus infections across mouse strains and disease models with roles for signaling pathways involvi

299 ology, now provide a means to probe cellular disease models with unprecedented throughput and informa

300 o overcome them, and advances in preclinical disease models with which the most promising systems may